Nurix Therapeutics, Inc. has announced a webcast conference call scheduled for June 12, 2025, at 8:00 a.m. ET to discuss new data from its ongoing Phase 1 clinical trial of bexobrutideg (NX-5948), ...

John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90 and 33% achieved IGA 0/1 Cohort 1-4 have demonstrated positive safety and efficacy results in patients who have received prior ...

HOUSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (MBRX), (“Moleculin” or the “Company”), today announced positive results from the Emory University physician-sponsored Phase 1 ...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been ...

Company to discuss data today on its first quarter 2025 business update conference call and webcast at 4:30 pm ET / 1:30 pm PT “We continue to be encouraged by the results from our Phase 1 trial of ...